Market Research Report
Malaria Diagnostics - Global Market Outlook (2017-2023)
|Published by||Stratistics Market Research Consulting||Product code||599868|
|Published||Content info||158 Pages
Delivery time: 2-3 business days
|Malaria Diagnostics - Global Market Outlook (2017-2023)|
|Published: December 1, 2017||Content info: 158 Pages||
According to Stratistics MRC, the Global Malaria Diagnostics market is accounted for $609.63 million in 2016 and is expected to reach $869.26 million by 2023 growing at a CAGR of 5.2%. Rising demand and increasing need for high-quality and cost-efficient diagnostic methods, advent of advanced technologies and increasing investment in research and development of novel therapeutics are some of the key factors boosting the market growth. However, rising demand for low cost diagnostic tests and technological complications are limiting the growth of the market.
Malaria is one of the most widespread life-threatening diseases, commonly occurring in the tropical and sub-tropical regions. Globally, around 3.2 billion populace still remains at the increased risk of the disease. As per the WHO estimates, September 2015, 214 million malarial cases were detected in 2015, and the number of fatalities was estimated to be 438,000 during the same period. Malaria diagnosis is conducted using various techniques such as molecular diagnostics, rapid diagnostic tests (RDTs), and by detecting the presence of parasites using microscopy.
Rapid Diagnostic Tests (RDT)'s are mostly used, where microscopy examination is not feasible, especially in remote areas with restricted access to quality microscopy services or poor healthcare infrastructure. In addition, they are user-friendly, provide less turnaround time and need low-skilled labor force. Thus, these factors are expected to be some of the key factors attributed for the growth of the RDT diagnostics at a global level.
Some of the key players in global malaria diagnostics market include Bio-Rad Laboratories, Inc., Wako Chemicals, Inc, Siemens Healthcare, Premier Medical Corporation, Ortho-Clinical Diagnostics, Novartis Diagnostics, Life Technology, Leica Microsystems, BioMerieux, Beckman Coulter/Danaher, Alere Inc., Access Bio Inc., Abbott Laboratories, Sysmex Partec GmbH, Nikon Corporation and Olympus Corporation.
What our report offers: